Study to Improve Outcomes for Survivors of Traumatic Brain Injury in Latin America

October 31, 2012 updated by: University of Washington

Traumatic Brain Injury in Latin America: Lifespan Analysis

People who survive severe traumatic brain injury (TBI) live with profound cognitive impairments that alter their developmental course and define their future possibilities. Worldwide, TBI is the leading cause of death and disability among children and adolescents (Murgio, 2000). In the United States, the annual incidence of TBI is six times greater than that of multiple sclerosis, HIV/AIDS, spinal cord injury, and breast cancer combined [Centers for Disease Control, American Cancer Society, National Multiple Sclerosis Society]. The burden of TBI may be even greater in developing countries, due to civil unrest and war, and to the absence of mandated prevention such as seat belt laws.

The long-term objective of the investigators' research group is to improve outcomes for survivors of TBI in Latin America. To that end, the investigators have created a structure for professionals and institutions involved in the treatment of TBI to generate research; to facilitate education, standardization, certification, the dissemination of information and resources; and to foster the development of evidence-based guidelines. The structure is the Latin American Brain Injury Consortium (LABIC).

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The objective of this application is to establish a network of Centers of Excellence within LABIC that will, in collaboration with U.S. partners, conduct research and training programs about TBI. To that end, this project will include scientific investigation and capacity building.

The primary focus for scientific investigation is to conduct a high quality randomized controlled trial addressing a question of critical importance to the management of TBI worldwide:

• Does the use of information provided by intracranial pressure (ICP) monitoring to direct treatment of patients with TBI improve medical practice and patient outcomes in a developing country? This trial will be conducted in three trauma centers in Bolivia, in which the infrastructures and practice patterns are optimal for strong internal validity, while at the same time the level of resources is representative of trauma care as practiced in the developing world.

The secondary focus for scientific investigation is to conduct a prospective study of TBI in seven trauma centers in Bolivia, Brazil, Argentina, Colombia, and Ecuador that represent the variation in access to and use of resources in the developing world. This study will address two questions of vital importance to management of TBI in developing countries:

  • To what extent do the findings from the randomized trial about ICP monitoring in particular, and brain injury care in general, generalize to diverse populations of TBI patients in Latin America?
  • What is the association between resources and outcomes from TBI in developing countries? To build capacity, we will provide education, equipment, and structure, and will foster the collaborations established during the pilot R21 phase of this project. Our commitment is that LABIC becomes completely independent as a research entity. At the end of the funding period LABIC constituents will be able to identify important research questions, design the research, write successful proposals for funding, carry out strong studies, analyze and interpret the data, submit successful publications to internationally recognized peer reviewed journals, and disseminate information across Latin America.

Our specific aims are:

Specific Aim#1: In a randomized controlled trial in 3 trauma centers in Bolivia, test the effect on outcomes of management of severe TBI guided by information from ICP monitors vs. a standard empiric protocol.

Hypothesis #1: Patients with severe TBI whose acute care treatment is managed using ICP monitors will have significantly lower mortality and better neuropsychological and functional recovery at 6 months post-trauma than those whose treatment is managed with the standard protocol.

Hypothesis #2: The incorporation of ICP monitoring into the care of patients with severe TBI will minimize secondary complications and decrease length of stay in intensive care unit (ICU).

Specific Aim #2: In a prospective, observational study conducted in trauma centers in Latin America, test the association between resource availability/medical management and outcomes for patients with severe TBI.

Hypothesis #3: The association between treatment and outcomes for patients with severe TBI identified in the randomized trial of ICP monitoring will generalize to the population in the prospective, observational, multi-center, multi-national study.

Hypothesis #4: Variations in resource availability and medical management will be significantly associated with mortality and functional recovery for patients with severe TBI, after controlling for patient and injury characteristics.

Specific Aim #3: Establish a network of research centers with investigators trained and skilled in the design, conduct, and funding of research programs to address TBI and other brain disorders in Latin America.

In fulfilling these aims, we will answer important research questions about patient characteristics, treatment, and outcomes from TBI in an environment of limited resources, aspects of which will generalize to other developing countries as well as to the developed world. In a developing country, we will test the effectiveness of technology considered pivotal to brain trauma treatment in the developed world - the ICP monitor. The outcome of this trial may serve to standardize practice, improve outcomes, and mobilize resources worldwide. A randomized controlled trial of ICP monitoring has never been performed. As specifically stated in the Guidelines for the Management of Severe Brain Injury (Bullock et al., 1996), this is a critical gap in the evidence base that supports the role of ICP monitoring in TBI care. As such, the results of the RCT as performed in Bolivia will have global implications regardless of the level of development of the trauma system.

We will also establish sustainable capacity to conduct research about TBI in Latin America. Within the structure of LABIC, we will create a cadre of professionals who are trained in clinical research and equipped to carry out studies that answer questions important to Latin America. These studies will establish a literature base from which Latin American treatment guidelines will be generated. With training in cognitive assessment, we will introduce a new discipline into many of the Latin American medical systems that will provide an understanding of the unique and profound disabilities associated with brain disorders.

Study Type

Interventional

Enrollment (Anticipated)

324

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Bolivia
      • Cochabamba, Bolivia
        • Hospital Viedma
      • Santa Cruz de la Sierra, Bolivia
        • Hospital Japones
      • Santa Cruz de la Sierra, Bolivia
        • Hospital San Juan de Dios
      • Tarija, Bolivia
        • Hospital San Juan de Dios
  • Ecuador
      • Espejo, Ecuador
        • Hospital de Especialidades Eugenio Espejo
      • Guayaquil, Ecuador
        • Hospital Luis Vernaza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • admission to study hospital within 24 hours of injury
  • closed head trauma
  • Glasgow Coma Scale (GCS) < 8 on admission or if intubated, GCS Motor < 5, within first 48 hours after injury
  • No foreign object in brain parenchyma

  • Randomized:

    • within 24 hours of injury [for patients with GCS < 8 on admission] or
    • within 24 hours of deterioration [patients deteriorating to GCS < 8 within 48 hours of injury]
  • Age > 12

Exclusion Criteria:

  • GCS of 3 with bilateral fixed and dilated pupils and/or decision to not actively treat prior to enrolment into study
  • No beds available in ICU
  • No ICP monitor available
  • Pregnancy
  • Prisoner
  • No consent
  • Non-survivable injury
  • Other (e.g., Pre-injury life expectancy under 1 year)
  • Pre-existing neurological disability that would not allow follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ICP monitoring
Care based upon intracranial pressure.
Device: Parenchymal Intracranial pressure monitor
Treatment based on readings from Parenchymal intracranial pressure monitor.
Other Names:
  • Integra Life Sciences Camino Intracranial Monitor
Active Comparator: Usual Care
Treatment based on clinical and imaging without intracranial pressure monitoring.
Other: Treatment based on clinical and imaging observations
Treatment based on clinical and imaging observations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
In a randomized controlled trial in 3 trauma centers in Bolivia, test the effect on outcomes of management of severe TBI guided by information from ICP monitors vs. a standard empiric protocol.
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Washington

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

Investigators

  • Principal Investigator: Randall M Chesnut, MD, University of Washington, Harborview Medical Center, Seattle, WA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2007

Primary Completion (Actual)

April 1, 2012

Study Completion (Anticipated)

March 1, 2013

Study Registration Dates

First Submitted

February 11, 2010

First Submitted That Met QC Criteria

February 12, 2010

First Posted (Estimate)

February 15, 2010

Study Record Updates

Last Update Posted (Estimate)

November 1, 2012

Last Update Submitted That Met QC Criteria

October 31, 2012

Last Verified

October 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 33888-B
  • 1R01NS058302 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injuries

Clinical Trials on Treatment based on clinical and imaging observations

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe